[Safety and pharmacology of aspoxicillin in healthy volunteers]. 1985

K Matsumoto, and H Shishido, and Y Uzuka, and T Nagatake, and M Yamamoto, and Y Sakuma, and I Maezawa, and T Yamaguchi

Aspoxicillin (ASPC), a new injectable semisynthetic penicillin, was administered to healthy volunteers to elucidate its safety and pharmacokinetics. No abnormalities obviously attributable to ASPC were observed in the examinations covering subjective and objective symptoms, blood pressure, heart rate, respiratory rate, electrocardiogram and body temperature, as well as in hematology, blood chemistry and urinalysis. There were slight increase in LDH (1 case), Al-P (1 case) and blood-glucose levels (2 cases) at 2 or 4 weeks after the administration with intravenous bolus consecutive injection (1 g X 1 or 2/day, 8 to 10 times), but these increases were not considered to be attributable to ASPC. When ASPC was administered by consecutive intravenous bolus injection, there observed no tendency of accumulation of the drug in serum or urine. When 1 g of ASPC was given intramuscular (i.m.), intravenous injection (i.v.) and intravenous drip infusion (d.i.) route, the maximum antibiotic levels in serum reached 25.2 micrograms/ml, 118.2 micrograms/ml and 70.3 micrograms/ml at 0.75 hour, 0.08 hour and 1 hour after the administration, respectively. The biological half-lives of ASPC attained by these 3 different routes were as follows: 1.73 hours (i.m.), 1.65 hours (i.v.) and 1.44 hours (d.i.). In a cross-over test with piperacillin (PIPC), serum levels of ASPC were higher than those of PIPC and half-lives of ASPC were longer. The 8 hours urinary recovery of ASPC was 75.9% after intravenous injection, 74.6% after intramuscular injection and 88.0% after intravenous drip infusion. Most of urinary recovery was excreted within 4 hours after administration regardless of dose levels, frequency of dosing or administration route. Thin layer chromatographic bioautography was conducted with the samples of serum and urine collected from subjects received ASPC. No antibacterial metabolite was observed in the serum obtained 2 hours after administration but a metabolite identified as amoxicillin was detected in a part of urine samples collected after 8 to 10 hours after the injection.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010878 Piperacillin Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics. AB-Piperacillin,Cl-227193,Pipcil,Pipera-Hameln,Piperacillin Curasan,Piperacillin Fresenius,Piperacillin Hexal,Piperacillin Monosodium Salt,Piperacillin Sodium,Piperacillin-Ratiopharm,Pipercillin,Pipracil,Pipril,T-1220,T1220,AB Piperacillin,Cl 227193,Cl227193,Curasan, Piperacillin,Monosodium Salt, Piperacillin,Pipera Hameln,Piperacillin Ratiopharm,Salt, Piperacillin Monosodium,Sodium, Piperacillin,T 1220
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

K Matsumoto, and H Shishido, and Y Uzuka, and T Nagatake, and M Yamamoto, and Y Sakuma, and I Maezawa, and T Yamaguchi
January 2015, The journal of headache and pain,
K Matsumoto, and H Shishido, and Y Uzuka, and T Nagatake, and M Yamamoto, and Y Sakuma, and I Maezawa, and T Yamaguchi
November 1979, Antimicrobial agents and chemotherapy,
K Matsumoto, and H Shishido, and Y Uzuka, and T Nagatake, and M Yamamoto, and Y Sakuma, and I Maezawa, and T Yamaguchi
March 2022, Clinical pharmacology in drug development,
K Matsumoto, and H Shishido, and Y Uzuka, and T Nagatake, and M Yamamoto, and Y Sakuma, and I Maezawa, and T Yamaguchi
October 1989, Investigative radiology,
K Matsumoto, and H Shishido, and Y Uzuka, and T Nagatake, and M Yamamoto, and Y Sakuma, and I Maezawa, and T Yamaguchi
July 2007, European journal of clinical pharmacology,
K Matsumoto, and H Shishido, and Y Uzuka, and T Nagatake, and M Yamamoto, and Y Sakuma, and I Maezawa, and T Yamaguchi
March 2016, Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology,
K Matsumoto, and H Shishido, and Y Uzuka, and T Nagatake, and M Yamamoto, and Y Sakuma, and I Maezawa, and T Yamaguchi
December 2012, Arzneimittel-Forschung,
K Matsumoto, and H Shishido, and Y Uzuka, and T Nagatake, and M Yamamoto, and Y Sakuma, and I Maezawa, and T Yamaguchi
June 2022, Aerospace medicine and human performance,
K Matsumoto, and H Shishido, and Y Uzuka, and T Nagatake, and M Yamamoto, and Y Sakuma, and I Maezawa, and T Yamaguchi
March 2005, Intensive care medicine,
K Matsumoto, and H Shishido, and Y Uzuka, and T Nagatake, and M Yamamoto, and Y Sakuma, and I Maezawa, and T Yamaguchi
May 1996, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!